Wojcicki last spring first offered to buy the company and take it public. Anne Wojcicki, the CEO of pioneering genetic testing company 23andMe, is open again to a third-party takeover of the company.

SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human ...

The Board of Directors of 23andMe previously formed the Special Committee, which is comprised of independent directors, to review strategic alternatives that may be available to 23andMe. The ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year ...

Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business ...

SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) (“23andMe” or the “Company”), a leading human genetics company ...